# A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors

Source: https://onco.cc/trials/nct07466160/  
OnCo record `nct07466160` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Cisplatin and Carboplatin in advanced solid tumours, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.

## Summary

A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07466160 by Mabwell (Shanghai) Bioscience Co., Ltd., with 280 participants planned, started 2026-02-11 and due to reach its primary completion in 2027-12-31. Interventions recorded: 7MW3711, JS207, Cisplatin and Carboplatin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07466160
- Phase: 1/2
- Setting: A Multi-center, Open-label, Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of 7MW3711 in Combination With JS207 With or Without Chemotheray in Patients With Advanced Solid Tumors
- Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
- Enrolled: 280

## Sources

- ClinicalTrials.gov NCT07466160: https://clinicaltrials.gov/study/NCT07466160

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/)

---
JSON: https://onco.cc/api/v1/entities/nct07466160.json